105 results
6-K
EX-99.3
SNY
Sanofi
2 May 24
Current report (foreign)
3:52pm
of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy, all being qualified as independent Directors.
On the proposal of the Appointments, Governance
F-3ASR
EX-1.1
SNY
Sanofi
4 Apr 24
Automatic shelf registration (foreign)
2:07pm
of the requirements of Article 9(8) of the MiFID Product Governance rules under EU Delegated Directive 2017/593, as amended (the “Product Governance Rules … ”), regarding the mutual responsibilities of manufacturers under the Product Governance Rules, each of [ ] and [ ] (each a “Manufacturer” and together
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
of a product-related controversy due to increased transparency on the issue and by performance increases in the Governance and Environmental dimensions
6-K
EX-99.1
SNY
Sanofi
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
update
Sanofi was recognized as one of the most sustainability-committed companies in an ESG (Environment, Social, Governance) Evaluation performed … by the above-peer environmental performance.
On governance performance:
–Sanofi's Board of Directors, recognized for its excellent performance
6-K
EX-99.2
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
pipeline, refer to Section G/ of this half-year management report.
A.3. OTHER SIGNIFICANT EVENTS
A.3.1 CORPORATE GOVERNANCE
The Combined General … not be renewed because he had reached the age limit stipulated in our Articles of Association. On a proposal from the Appointments, Governance and CSR
6-K
EX-99.1
whpbi234nf1hi2oem
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
6-K
EX-99.1
ahgrdn0lj3m
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.1
auwwogizk03 wuj
12 Sep 22
Evolution of the Board of Directors
7:07am
6-K
EX-99.2
smgrd
28 Jul 22
Condensed Half-year Consolidated Financial Statements
6:17am
6-K
EX-99.1
ml4kq7
9 May 22
Approval of the financial statements for the fiscal year 2021
2:29pm
6-K
EX-99.1
s2c5tl
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
EX-99.1
stirjrc2
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
EX-99.1
92075w9
31 Mar 22
Current report (foreign)
12:12pm
6-K
EX-99.1
54b4smg8yy1oyvgf1p
15 Mar 22
Sanofi recognized by S&P as one of the most sustainability-committed companies
3:52pm
6-K
iyjgwym4dsc
21 Dec 21
Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
1:28pm
6-K
EX-99.1
2x3 o23ew5b6xbkxlcj
21 Dec 21
Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
1:28pm
6-K
EX-99.1
m12qws3ur7gxrj8
28 Oct 21
Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC
11:19am
SC TO-T
EX-99
157cyr3mj1w8ay13jm
16 Aug 21
Third party tender offer statement
8:09am